Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 12-Month High at $129.35

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $129.35 and last traded at $129.35, with a volume of 908 shares changing hands. The stock had previously closed at $124.45.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. BTIG Research began coverage on Zealand Pharma A/S in a research report on Thursday, March 7th. They issued a “buy” rating for the company. Cantor Fitzgerald assumed coverage on shares of Zealand Pharma A/S in a report on Tuesday, May 21st. They set an “overweight” rating for the company.

Zealand Pharma A/S Stock Performance

The company has a quick ratio of 12.28, a current ratio of 12.30 and a debt-to-equity ratio of 0.10. The firm has a 50 day moving average price of $94.45 and a two-hundred day moving average price of $83.27.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, May 16th. The company reported ($0.54) EPS for the quarter. The firm had revenue of $2.20 million during the quarter. Zealand Pharma A/S had a negative net margin of 213.77% and a negative return on equity of 36.96%. Analysts forecast that Zealand Pharma A/S will post -2.54 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.